Alopecia areata is a chronic, immune-mediated disease characterized by non-scarring hair loss, now recognized by clinical experts as a systemic inflammatory condition rather than a mere cosmetic concern. Affecting the scalp, eyebrows, and eyelashes, the disorder requires medical intervention to manage its profound psychosocial impact and underlying biological inflammation.
Clinical Essentials for Patient Understanding
- Severity Thresholds: Doctors categorize the condition using the Severity of Alopecia Tool (SALT) score, where 50% or more hair loss typically qualifies as severe disease requiring systemic, rather than just topical, treatment.
- Beyond Steroids: While intralesional injections are common for mild cases, moderate to severe disease often necessitates systemic therapies to address the broader inflammatory response.
Defining the Medical Reality of Alopecia Areata
He identifies the condition as a systemic inflammatory disease, noting that patients exhibit elevated markers of inflammation not only in the skin where hair loss occurs but also within the bloodstream.
Unlike androgenetic alopecia, which is largely hormonal and patterned, alopecia areata represents an autoimmune dysfunction. The psychosocial burden—the mental and emotional weight of the condition—is significant, often impacting the daily quality of life in ways that purely cosmetic hair loss does not. Clinicians are now urged to treat the condition with the same diagnostic rigor applied to other autoimmune disorders.
Clinical Scoring and the Shift to Systemic Therapy
Determining the appropriate treatment path requires a precise assessment of disease extent. The industry-standard metric is the SALT score, which calculates the percentage of scalp hair involvement. According to Dr. Ungar, a SALT score of 50 or greater defines severe disease. However, clinical practice often extends beyond this single metric. Dr. Ungar utilizes a more comprehensive scale that accounts for eyebrow and eyelash involvement, the speed at which hair loss is progressing, and the patient’s failure to respond to initial therapies over a six-month period.
For mild cases, clinicians often rely on topical treatments or intralesional steroid injections. While these can be effective for localized patches, they present clear limitations. Repeated injections can cause skin atrophy—a thinning of the skin—and the sheer volume of injections required for extensive hair loss becomes a significant burden for the patient. Consequently, the medical consensus has shifted toward systemic therapies for patients whose disease is categorized as moderate to severe.
| Treatment Category | Primary Indication | Clinical Limitations |
|---|---|---|
| Topical Anthralin/Steroids | Mild alopecia | Inconsistent efficacy; rarely effective in adults |
| Intralesional Steroids | Localized/Mild disease | Burden of frequent injections; risk of skin atrophy |
| Systemic Therapies | Moderate to Severe (SALT ≥50) | Requires ongoing monitoring for systemic side effects |
Regulatory Framework and Treatment Access
In the United States, medical necessity for treatment is strictly defined by clinical policy. According to Aetna’s Clinical Policy Bulletin, systemic therapies—including oral JAK inhibitors such as baricitinib and ritlecitinib—are considered medically necessary for patients with extensive or severe disease who have not responded to conventional approaches. This policy highlights a clear distinction: while topical anthralin or glucocorticoids may be sufficient for mild cases, more aggressive intervention is supported for patients with greater than 50% scalp hair loss.
References
- Aetna Clinical Policy Bulletin: Alopecia Areata (0423)
- "Two Phase 3 Trials of Baricitinib for Alopecia Areata." The New England Journal of Medicine.
